Abstract 23P
Background
Breast cancer is the second most common cancer in women worldwide and contributes to a significant amount of mortality annually. It also contributes significantly to cancer-related morbidity in Bali especially in Gianyar district where most of the breast cancers are diagnosed at an advanced stage. Therefore, we aimed to evaluate the correlation between the levels of knowledge with the attitude of local-productive age women toward SADARI (breast self-assessment).
Methods
A family-based cross-sectional study was conducted in August 2018 in the Pejeng Kaja village, Ubud, Bali. The level of knowledge such as the definition of breast cancer, risk factors, therapy, prevention and several aspects of SADARI method was examined using a validated questionnaire. All of the data were subsequently recorded into SPSS for analysis.
Results
122 respondents were enrolled in this study with a mean age of 45.65±9.51 years. More than half of the respondents were having at least high school education and 55% know breast cancer. However, 46.7% were known about SADARI. 5 variables were significantly associated with the status of SADARI knowledge namely: level of education, knowledge about breast cancer, breast cancer prevention, and how to perform SADARI as well as the frequency of SADARI performance by respondents (p < 0.05). Risk assessment for each variable showed that all variables had OR > 5 with the biggest OR on the level of education (OR: 7.2; 95%CI: 3.56-14.75).
Conclusions
We conclude that the level of education, knowledge about breast cancer, early symptoms of breast cancer, breast cancer prevention, and how to perform SADARI as well as frequency of SADARI performance influenced the performance rate of SADARI in reproductive women in Pejeng Kaja with low level of education posed the greatest risk of not performing SADARI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract